BioLargo, Inc. is spotlighting new clinical data that could signal a shift in how complex wounds are treated, following a key presentation at one of the industry’s leading gatherings.
The company announced that its subsidiary, Clyra Medical Technologies, shared results for its ViaCLYR wound irrigation solution at the Boswick Symposium, held in Maui in late January. The findings, presented by wound care specialist Marcus Gitterle, highlighted what clinicians described as rapid and notable improvements across a range of difficult-to-treat wounds.
The evaluation covered approximately 36 cases across four wound clinics over four months, including diabetic foot ulcers, venous leg ulcers, pressure injuries, and complex surgical wounds. According to the presentation, ViaCLYR demonstrated strong antimicrobial performance alongside enhanced healing outcomes—without any reported adverse reactions.
Among the most striking observations were rapid reductions in wound drainage, improved tissue quality early in treatment, and faster closure of wound tunnels, a complication that can be particularly difficult to manage. Clinicians also reported visible improvements in wound edges, new skin formation, and overall wound size reduction.
ViaCLYR is powered by Clyra’s proprietary copper-iodine complex solution, known as Clyrasept, which is designed to deliver broad-spectrum antimicrobial activity while remaining compatible with healthy tissue. The technology aims to address a longstanding challenge in wound care: eliminating harmful bacteria without damaging the body’s natural healing processes.
Dr. Gitterle described the results as both “remarkable” and “unusual,” particularly in patients with chronic, fibrotic wounds that had previously shown limited progress. In these cases, wounds transitioned more quickly into active healing states, with increased granulation and reduced depth.
The presentation also emphasized the potential role of copper in supporting healing, alongside the solution’s ability to cleanse wounds and suppress biofilm—a key factor in chronic wound persistence.
Executives at BioLargo say the findings provide meaningful validation as the company expands access to ViaCLYR. CEO Dennis P. Calvert noted that real-world clinical outcomes are critical in driving adoption, particularly when clinicians observe measurable improvements in challenging cases.
The Boswick Symposium, known for bringing together leading experts in wound care, serves as a platform for evaluating emerging treatments and sharing frontline clinical insights. For Clyra Medical, the positive reception signals growing interest in technologies that combine antimicrobial strength with tissue-friendly design.
As the company continues its commercial rollout, additional studies and presentations are planned throughout 2026, with a focus on building an evidence-based case for broader clinical use.